TONIX Pharmaceuticals, Inc. Completes Enrollment In BESTFIT Trial Of TNX-102 SL For Fibromyalgia

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, May 12, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, today announced that it has completed enrollment in the BESTFIT trial of TNX-102 SL for fibromyalgia, after having achieved the randomization goal of 200 subjects.

Help employers find you! Check out all the jobs and post your resume.

Back to news